LA Peptides

PRODUCT
Semax / Selank / Dihexa spray

ORDER
GSA-2026-000080

SAMPLE
LA-SEMSELDIHEXA-20261127

LABEL
10 / 10 / 10 mg per bottle

UPLOAD DATE
Nov 27, 2026

BATCH
2618



SAMPLE PHOTO

IDENTITY

Semax / Selank / Dihexa

Pass · Identity confirmed

PURITY

Semax	99.44%
Selank	99.52%
Dihexa	99.91%

Lot 2618 · Pass
HPLC-UV, 214 nm · 2 injections

HEAVY METALS

Pass

USP <232>, ICP-MS: Pb, Cd, Hg, As, Co, V, Ni

NET CONTENT

Semax	9.92 mg
Selank	10.10 mg
Dihexa	9.97 mg

Per bottle
99.2% / 101.0% / 99.7% of label claim

Endotoxins Spike recovery 84% — **Pass**

Fentanyl screen Lot 2618 — **Pass**

Reference plots

HPLC CHROMATOGRAM — T7 · 5/5/5 mg spray · 214 nm



MASS SPECTRUM — T6 · spray · strength and scan time unreported



APPROVED FOR RELEASE

Ian Ebert, Laboratory Director

Signed electronically
27 Nov 2026, 21:17 UTC
Release record: last page

Results are not covered by ISO/IEC 17025 accreditation.

The sample

Semax / Selank / Dihexa spray · Lot 2618

Customer	**LA Peptides**	Prepared	**Nov 25, 2026**
Order	**GSA-2026-000080**		
Sample	**LA-SEMSELDIHEXA-20261127**	Tested	**Nov 25, 2026**
Label	**Semax / Selank / Dihexa spray · 10 / 10 / 10 mg per bottle**	Tests	**Identity, purity, net active content, fentanyl screen, bacterial endotoxins, elemental impurities**

Graphs

Reference plots

HPLC CHROMATOGRAM

T7 · 5/5/5 mg spray · 214 nm



MASS SPECTRUM

T6 · spray · strength and scan time unreported



Results

Lot 2618 results · Record IDs identify reference values

Identity	**Pass.** Identity confirmed for Semax / Selank / Dihexa. Lot 2618.
Purity	**Pass.** Lot 2618. Semax 99.44% / Selank 99.52% / Dihexa 99.91%. HPLC-UV, 214 nm · 2 injections
Net active content	**Pass.** Semax 9.92 mg / Selank 10.10 mg / Dihexa 9.97 mg per bottle 99.2% / 101.0% / 99.7% of label claim
Fentanyl screen	**Pass.** Lot 2618.
Bacterial endotoxins	**Pass.** Lot 2618. Spike recovery 84%. T6 · Spray strength unspecified. Both replicates passed. Decision threshold and numerical result unreported.
Elemental impurities	**Pass.** Lot 2618. USP <232>, ICP-MS: Pb, Cd, Hg, As, Co, V, Ni. No panel reported for the Semax/Selank/Dihexa spray. T3 tested Semax/Selank/Pinealon.

Zoomed views

Reference plots

HPLC, SMALL PEAKS

T7 · 5/5/5 mg spray



ION TRACE

T8 · Selank · 10 mg powder vial



Impurities

Individual impurity peaks

PEAK (MIN)	AMOUNT	WHAT IT IS
—	—	T7 · Peaks at 2.575 and 6.225 min. Constituent assignments unreported.

> No batch 2618 impurity peak table was supplied.

How it was tested

T1 · Purity and content, 5/5/5 mg spray. T6 · Identity and endotoxin, strength unspecified. The 10/10/10 mg formulation remains unverified in these records.

T7 · 5/5/5 mg spray chromatogram. Ion traces show Semax vial S6, Selank vial T8 and Dihexa capsule D4.

Notes

The attached data tables list the reference materials for each record ID.

Release

Release date Nov 27, 2026. Unsigned copy.

Customer and order	LA Peptides · GSA-2026-000080
Sample and report	LA-SEMSELDIHEXA-20261127 · Semax / Selank / Dihexa spray · Lot 2618
Report reference	Unsigned draft
Certificate accession	
Date and time (UTC)	Nov 27, 2026
Approval reference	
Original report SHA-256	

Gold Standard Analytics

Release record

goldstandardanalytics.com Report GSA-COA-CUST-SEMAX-SELANK-DIHEXA-SPRAY-UPL-0e1c92fbb3ad · Certificate GSA-2026-791713

Customer and order	LA Peptides · Custom sample (no order)
Sample and report	Semax/Selank/Dihexa Spray · Certificate of Analysis
Report reference	GSA-COA-CUST-SEMAX-SELANK-DIHEXA-SPRAY-UPL-0e1c92fbb3ad
Certificate accession	GSA-2026-791713
Released and signed by	Ian Ebert, Laboratory Director
Date and time (UTC)	2026-11-27 21:17:13Z
Signature meaning	Approved for release. The signer reviewed this report and approved its release to its customer.
Approval reference	650dc280-5d64-41d1-b930-f46145f8dd3a
Electronic signature	Signed electronically in a signed-in GSA staff account.
Original report SHA-256	d42b779e7f305ab5876e1d1f3f72eb59ce2f41f6e3662fb6cbcd03c8f07cf549
Verify this certificate	https://goldstandardanalytics.com/coa/GSA-2026-791713

Scan to view this certificate online

Signature



Ian Ebert, Laboratory Director

Results are not covered by ISO/IEC 17025 accreditation.
Results relate only to the sample as received and tested.